TABLE 80Times to quitting treatments

Treatmenta95% CIb (years)95% CIMean (years)Source
TNF inhibitors0.7010.634 to 0.7683.2113.022 to 3.4124.06BSRBR submission123
RTX0.4740.403 to 0.5455.13.742 to 6.95111.31REFLEX LTE139
ABT0.810.734 to 0.8865.495.166 to 5.8346.17BMS submission205
LEF10.905 to 1.0955.985.627 to 6.3555.98GPRD database206
GST0.480.434 to 0.5261.811.703 to 1.9233.91
CyA0.50.452 to 0.5484.354.094 to 4.6238.70
AZA0.390.353 to 0.4274.354.094 to 4.62315.53

GPRD, General Practice Research Database; Normal distributions used for parameter: a, log-normal for parameter; b, Standard errors for TNF inhibitors and RTX estimated from data. For other treatments, the same proportional variability as for TNF inhibitors has been assumed. Mean time on treatment based on the point estimate of the parameters.

From: 4, Assessment of cost-effectiveness

Cover of Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation
Adalimumab, Etanercept, Infliximab, Rituximab and Abatacept for the Treatment of Rheumatoid Arthritis After the Failure of a Tumour Necrosis Factor Inhibitor: A Systematic Review and Economic Evaluation.
Health Technology Assessment, No. 15.14.
Malottki K, Barton P, Tsourapas A, et al.
Southampton (UK): NIHR Journals Library; 2011 Mar.
© 2011, Crown Copyright.

Included under terms of UK Non-commercial Government License.

PubMed Health. A service of the National Library of Medicine, National Institutes of Health.